1986 Index

1986 I N D E X A Aching: in fibrositis, Nov. 670, 675 Acquired immunodeficiency syndrome (see AIDS) Acyclovir in genital herpes patients free of recurrence after, Dec. 784 time without recurrence, Dec. 785 virus shedding after, Dec. 782 Adenovirus: types 40 and 41, in diarrhea, Apr. 211-212 Aeromonas hydrophila: in diarrhea, Apr. 199-201 Afterload effect on stroke volume, Aug. 457 in myocardial infarction, acute, Aug. 456-459 Age: of onset of panic disorder and agoraphobia, July 401 Aged: postural instability of, Mar. 152 Agoraphobia (see Panic disorder and agoraphobia) AIDS gastrointestinal conditions in, Apr. 228 oral herpes in, Dec. 744 Allergic reactions: to nonsteroidal anti-inflammatory drugs, Jan. 27 Amyotrophies: in multiple sclerosis, Sept. 561 Anal neoplasms: curability, Oct. 631-632 Ann Arbor staging classification: of Hodgkin's disease, Oct. 610 Anomalies: Chiari, Mar. 150-151 806

Antigen hepatitis B core, June 333 hepatitis B surface, June 331 prenatal screening for, June 356 hepatitis Be, June 333 Anti-inflammatory drugs, nonsteroidal adverse reactions to, Jan. 27-28 dosage, Jan. 23 glucocorticoids and, Jan. 28-34 pregnancy and, Jan. 28 in rheumatoid arthritis, Jan. 23-28 Antimalarials: in rheumatoid arthritis, Jan. 44-45 Antimicrobial agents: in infectious diarrhea, Apr. 238-239 Antiviral therapy: in genital herpes, Dec. 780-785 Anxiety disorders, principle features, July 396 neurosis (see Panic disorder and agoraphobia) symptoms, frequency of, July 417 Apheresis: in rheumatoid arthritis, Jan. 53 apoC-II: familial deficiency, May 262-263 Arthritis (see Rheumatoid arthritis) Aspartate aminotransferase (AST) determination: in non-A, non-B hepatitis, June 372 Asthenia: neurocirculatory, July 397 Ataxia: in multiple sclerosis, Sept. 583 ATM, Sept. 558-559

Atopic eczema: and herpes simplex, Dec. 744 Atrial pressure tracings: right, in right ventricular infarction and pericardial tamponade, Aug. 491 Azathioprine: in rheumatoid arthritis, Jan. 46-48 Azolid: in rheumatoid arthritis, Jan. 26 B Bacterial agents: in diarrhea, Apr. 176-207 Beta-sitosterol: in hyperlipoproteinemia, May 302 Behavior therapy: in panic disorder and agoraphobia, July 432 Benzodiazepine receptor: in panic disorder and agoraphobia, July 413-414 Bile acid squestering resins: in hyperlipoproteinemia, May 294-296 Biopsy: muscle, in myofascial pain syndromes, Nov. 712-713 Bladder disturbances: in multiple sclerosis, Sept. 582-583 Blood donor screening: and incidence of non-A, non-B hepatitis, June 377 Bowel disease, inflammatory, diarrhea in, Apr. 232-233 dysfunction in multiple sclerosis, Sept. 583 Breast neoplasms: curability, Oct. 637 Burkitt's lymphoma: curability, Oct. 634 Butazolidin: in rheumatoid arthritis, Jan. 26 C Caliciviruses: in diarrhea, Apr. 211

Calorie levels: food group servings for, May 282

Campylobacter in diarrhea, Apr. 190-195 differentiation from

Campylobacter-like organisms, Apr. 193 -like organisms in diarrhea, Apr. 195-197 differentiation from Campylobacter, Apr. 193 of gastric antrum, Apr. 197-198 Cancer: testicular, staging of, Oct. 617 Capillary wedge pressure: pulmonary, related to diastolic pressure in left ventricle, Aug. 455 Carpal tunnel syndrome, Jan. 62-63 Cataplexy, Mar. 137-139 Central nervous system: reactions to nonsteroidal antiinflammatory drugs, Jan. 28 Cerebellum: in posture, Mar. 133 Cerebrospinal fluid abnormalities: in multiple sclerosis, Sept. 565-568 Cervicitis: and herpes simplex virus, Dec. 755 Chemotherapy regimens glossary of, Oct. 598-599 for lymphoma, diffuse large-cell, Oct. 633 Chiari malformations, Mar. 150-151 Chin: in herpes simplex virus, Dec. 741

Chlamydia trachomatis in diarrhea, Apr. 204-207 prevalence in rectal infections, Apr. 205 Chloroquine: in rheumatoid arthritis, Jan. 44-45 Cholesterol levels: total serum, May 291 Circulation: anterior, ischemia, Mar. 141-142 807

Clinorih in rheumatoid arthritis, Jan. 24 Clofibrate: in hyperlipoproteinemia, May 297-299 Clostridium difficile: in diarrhea, Apr. 202-204 Cognitive therapy: in panic disorder and agoraphobia, July 434-435 Compactin: in hyperlipoproteinemia, May 302-303 Computed tomography: in multiple sclerosis, Sept. 564-565 Contractility: in acute myocardial infarction, Aug. 459 Corneal arcus: in hypercholesterolemia, May 266 Coronary heart disease, May 290 Cost-effectiveness: of hepatitis B vaccine, June 361 Cough syncope: and falls, Mar. 159-160 Counseling dietary, in hyperlipoproteinemia, May 285-288 educational, in genital herpes, Dec. 785-797 psychological, in genital herpes, Dec. 785-797 Counterpulsation: intra-aortic, in left ventricular dysfunction after myocardial infarction, Aug. 485-487 Cramps: muscle, Nov. 663 Cryptosporidium: in diarrhea, Apr. 219-221 CSF abnormalities: in multiple sclerosis, Sept. 565-568 Cutaneous herpes, treatment, Dec. 770-771 manifestations of toxic shock syndrome, Feb. 96 Cyclophosphamide: in rheumatoid arthritis, Jan. 48-49 Cytomegalovirus: in diarrhea, Apr. 212-213 808

Cytotoxic therapy: in rheumatoid arthritis, Jan. 46 D Delivery: and multiple sclerosis, Sept. 577-578 Delta agent (see Hepatitis, D virus) Demyelination: experimental, in multiple sclerosis, Sept. 545-547 Dermatologic reactions: to antiinflammatory drugs, Jan. 28 Dextrothyroxine: in hyperlipoproteinemia, May 300-301 Diarrhea, Apr. 173-244 abbreviations relating to, Apr. 173 adenoviruses in, types 40 and 41, Apr. 211-212 Aeromonas hydrophila in, Apr. 199-201 bacterial agents in, Apr. 176-207 in bowel disease, inflammatory, Apr. 232-233 caliciviruses in, Apr. 211 Campylobacter in, Apr. 190-195 Campylobacter-like organisms in, Apr. 195-197 Chlamydia trachomatis in, Apr. 204-207 Clostridium difficile in, Apr. 202-204 Cryptosporidium in, Apr. 219-221 cytomegalovirus in, Apr. 212-213 Entamoeba histolytica in, Apr. 215-217 Escherichia coli in, Apr. 176-184 enteric pathogens, Apr. 178-179 enteroadherent, Apr. 181-182 enteroinvasive, Apr. 182

enteropathogenic, Apr. 180-181 enterotoxigenic, Apr. 176-180 strain 0157:H7, Apr. 182-184 fecal leukocytes in, Apr. 235 in food poisoning, Apr. 225 Giardia lamblia in, Apr. 217-219 herpes simplex virus in, Apr. 213-215 infectious, Apr. 173-244 antimicrobial agents in, Apr. 238-239 diagnosis, Apr. 234-236 treatment, Apr. 236-240 in intestinal disease in homosexual men, Apr. 225-231 in immunosuppressed patients, Apr. 231-232 Isospora in, Apr. 222 mycobacterial infections in, Apr. 202-207 Norwalk virus in, Apr. 209-210 pararotavirus in, Apr. 209 parasitic infections in, Apr. 215-222 Plesiomonas shigeUoides in, Apr. 199-201 rotavirus in, Apr. 207-209 Salmonella in, Apr. 184-185 ShigeUa in, Apr. 185-186 in special settings, Apr. 222-233 travelers', infectious, Apr. 222-224 Vibrio in, Apr. 186-190 cholerae, Apr. 187-188 cholerae, non-O group 1, Apr. 188-189 fluvialis, Apr. 190 mimicus, Apr. 190 parahaemolyticus, Apr. 189-190 viral infections in, Apr. 207-215 virus particles in, small round, Apr. 210-211 Yersinia in enterocolitica, Apr. 201-202 pseudotuberculosis, Apr. 201-202

Diastolic pressures: in left ventricle, related to pulmonary capillary wedge pressure, Aug. 455 Diazepam binding inhibitor: in panic disorder and agoraphobia, July 414 Dietary counseling in hyperlipoproteinemia, May 285-288 treatment of hyperlipoproteinemia, May 279-288 determining appropriate phase, May 284 Diflunisal: in rheumatoid arthritis, Jan. 26 Dissemination: in space, in multiple sclerosis, Sept. 563 Diuretics: in left ventricular dysfunction after acute myocardial infarction, Aug. 473-474 Dolobid: in rheumatoid arthritis, Jan. 26 Donor screening: and incidence of non-A, non-B hepatitis, June 377 Drop attacks, Mar. 127-162 Drug(s) anti-inflammatory (see Antiinflammatory drugs) experimental, for rheumatoid arthritis, Jan. 53 in hyperlipoproteinemia (see Hyperlipoproteinemia, drugs in) in panic disorder and agoraphobia, July 427-432 Dystonias: movement-induced, Mar. 151-152

E Early experiences: in panic disorder and agoraphobia, July 415 809

Eczema: atopic, and herpes simplex, Dec. 744 Education: fibrositis, Nov. 700-701 Educational counseling: in genital herpes, Dec. 785-797 Effort syndrome, July 397 Electromyography: in myofascial pain syndromes, Nov. 711-712 Entamoeba histolytica: in diarrhea, Apr. 215-217 Epileptic seizures, Mar. 155-156 Escherichia coli (see Diarrhea, Escherichia coli in) Evoked potentials: in multiple sclerosis, Sept. 563-564 Exercise: muscle pain with, Nov. 663

F

Facial myokymia: in multiple sclerosis, Sept. 560-561 Falls, sudden unprovoked, Mar. 127-162 causes of, Mar. 128 Family studies: in panic disorder and agoraphobia, July 402-403 Fascial structures, Nov. 662 Fat: polyunsaturated, saturated and monounsaturated, May 287 Fatigue: in multiple sclerosis, Sept. 583-584 Fecal leukocytes: in diarrhea, Apr. 235 Feldene: in rheumatoid arthritis, Jan. 26 Felty's syndrome, Jan. 57-58 Fenofibrate: in hyperlipoproteinemia, May 303 Fenoprofen: in rheumatoid arthritis, Jan. 25 Fibromyalgia (See also Fibrositis) discussion of term, Nov. 659, 668 810

Fibromyositis: discussion of term, Nov. 668 Fibrositic nodule, Nov. 704 Fibrositis, Nov. 659-722 aching in, Nov. 670, 675 associated findings, Nov. 684-685 clinical findings, Nov. 672-674 definition of term, Nov. 659, 670 diagnosis, Nov. 685-688 differential, Nov. 685-688 discussion of term, Nov. 659, 668 education, Nov. 700-701 epidemiology, Nov. 673-674 historical perspective, Nov. 668-670 injection in, local, Nov. 702 local, Nov. 669 management, Nov. 699-704 medicolegal considerations, Nov. 702-703 MMPI T-scores in, Nov. 696 modulating factors, Nov. 675-676 muscle abnormalities in, Nov. 689-691 musculoskeletal pain in, diffuse, Nov. 670, 675 pathogenesis, Nov. 689-699 physical fitness and, Nov. 701 physical therapy in, Nov. 702 precipitating events, Nov. 674 prevalence, Nov. 672-673 primary, Nov. 672, 686 psychological studies in, Nov. 693-698 SCL-90-R T scores for, Nov. 697 secondary, Nov. 672, 686 signs, Nov. 675-685 sleep disturbance in, Nov. 676-677, 692-693 management, Nov. 701-702 stiffness in, Nov. 670, 675 symptoms, Nov. 675-685 tender points in, Nov. 670, 677-684 dolorimeter pressure required to produce tenderness over, Nov. 680, 681

location of, Nov. 679 prevalence of, Nov. 683 Fluid therapy: in left ventricular dysfunction after acute myocardial infarction, Aug. 472-473 Food group servings for different calorie levels, May 202 poisoning clinical syndromes, Apr. 226-227 diarrhea in, Apr. 225 Forrester clinical classification: of hemodynamic subsets in acute myocardial infarction, Aug. 470 Frank-Starling ventricular function curve, Aug. 453 effects of vasodilators on, Aug. 475 G Gastric (see Stomach) Gastrointestinal (See also Intestine) conditions in AIDS, Apr. 228 in homosexual men, Apr. 228 disease, infectious agents in, Apr. 175 reactions to nonsteroidal antiinflammatory drugs, Jan. 27 Gemfibrozil: in hyperlipoproteinemia, May 300 Genetic disorders: and hyperlipoproteinemia phenotype definition, May 260 Genetics of multiple sclerosis, Sept. 530-535, 541-542, 577 of panic disorder and agoraphobia, July 401-405 Genital herpes (see Herpes simplex virus, infection, genital)

Germ cell tumors: testicular, proposed scheme for development of, Oct. 616 Gestational trophoblastic neoplasms curability, Oct. 622-625 staging of, Oct. 623 Giardia lamblia: in diarrhea, Apr. 217-219 Gingivostomatitis, herpetic, Dec. 735 genital herpes and, Dec. 755 Globulin: immune, for prevention of hepatitis A virus, June 330 Glucocorticoids: and nonsteroidal anti-inflammatory drugs, Jan. 28-34 Glutamic oxaloacetic transaminase: serum, in non-A, non-B hepatitis, June 372 Glycolipids: of white matter, Sept. 537 Gold: and rheumatoid arthritis, Jan. 34-40 Golgi tendon organs, Nov. 662 H

Hand: useless hand syndrome in multiple sclerosis, Sept. 559-560 Head neoplasms: curability, Oct. 634-635 Heart disease, coronary, May 290 output decrease, and falls, Mar. 153 rate in acute myocardial infarction, Aug. 459-460 Heat sensitivity in multiple sclerosis, Sept. 562 management, Sept. 579 Hematologic reactions: to nonsteroidal antiinflammatory drugs, Jan. 28 Hemodynamic abnormalities in acute 811

Hemodynamic (cont.) myocardial infarction, Aug. 451-514 pathophysiology, Aug. 451-460 classification of patients with acute myocardial infarction, Aug. 468-472 Forrester, Aug. 470 monitoring in acute myocardial infarction, Aug. 460-464 Hepatitis A virus, June 321-331 clinical events, June 322-324 diagnosis, June 324-326 epidemiology, June 326-327 prevention, June 327-331 prophylaxis, postexposure, June 329-330 prophylaxis, preexposure, June 330 serologic events, June 323, 324-326 virologic events, June 322-324 virology, June 321-322 B

acute, June 334-337 chronic, June 337-339 core antigen, June 333 surface antigen, June 331 surface antigen, prenatal screening for, June 356 vaccine (see Vaccine, hepatitis B) B virus, June 331-363 clinical features, June 340-341 course of, factors affecting, June 339-340 diagnosis, June 341-342 epidemiology, June 342-346 immunoprophylaxis, active (see Vaccine, hepatitis B) immunoprophylaxis, passive, June 348-356 potential outcomes, June 340-341 prevention, June 346-363 812

prophylaxis, postexposure, June 349, 350, 351-352 prophylaxis, preexposure, June 349-350 serologic events, June 334-340 serologic patterns, interpretations, June 343 virologic events, June 334-340 virology, June 331-334 Be antigen, June 333 D virus, June 364-370 clinical events, June 365-368 diagnosis, June 368-369 discovery, June 364-365 epidemiology, June 369-370 prevention, June 370 schematic structure, June 364 serologic events, June 365-368 virologic events, June 365-368 virology, June 364-365 non-A, non-B, June 370-378 clinical features, June 370372 diagnosis, June 372 epidemiology, June 373-374 prevention, June 374-378 virologic features, June 370-372 viral, June 320-385 abbreviations in, June 320 Herniation syndromes: and falls Mar. 156-159 Herpes labialis (see Herpes simplex) Herpes simplex virus diagnostic considerations, Dec. 763-766 in diarrhea, Apr. 213-215 infection cutaneous nongenital, treatment, Dec. 770-771 genital (see below) in immunocompromised persons, treatment, Dec. 774-775

maternal, management plan. Dec. 773-777, 778-779 maternal, overview, Dec. 760-763 neonatal, overview, Dec. 760-763 neonatal, treatment, Dec. 777-780 in nonimmunocompromised persons, treatment, Dec. 772 oral (see below) type 1, treatment, Dec. 766-773 uncommon aspects, Dec. 742-747 infection, genital, Dec. 732-805 antiviral therapy, Dec. 780-785 counseling, educational and psychosocial, Dec. 785-797 initial, summary of, Dec. 751 overview, Dec. 747-760 from positive perspective, Dec. 795-797 recurrent, summary of, Dec. 751 ~'telling" sexual partner, suggestions for, Dec. 792 treatment, Dec. 780-785, 786 infection, oral, Dec. 732-805 clinical aspects, summary of, Dec. 743 clinical perspective, Dec. 733-742 natural course, summary of, Dec. 738-739 treatment, Dec. 770-771 Hodgkin's disease Ann Arbor staging classification of, Oct. 610 chemotherapy regimens, glossary of, Oct. 598 curability, Oct. 609-615 Homosexual men gastrointestinal conditions in, Apr. 228 intestinal disease in, Apr. 225-231 Hydrocephalus: and fails, Mar. 142

Hydroxychloroquine: in rheumatoid arthritis, Jan. 44-45 Hypercholesterolemia, May 258 causes, secondary, May 273-274 corneal arcus in, May 266 drugs in, May 288-303 familial, May 264-265 xanthoma in, tendinous, May 265 lipid lowering in, predictions of, May 284-285 treatment, nondietary and nonpharmacologic, May 304-307 Hyperemesis gravidarum, Oct. 623 Hyperlipidemia, May 252-311 familial combined, May 272 secondary causes, May 261 type III, tuberous xanthoma in, May 267 type V, eruptive xanthoma in, May 266 Hyperlipoproteinemia, May 258-279 beta-sitosterol in, May 302 bile acid sequestering resins in, May 294-296 classification, May 258-279 clofibrate in, May 297-299 compactin in, May 302-303 definition, May 258-279 dextrothyroxine in, May 300-301 dietary counseling in, May 285-288 dietary goals in, May 281 dietary intervention, assessment, May 288 dietary treatment, May 279-288 determining appropriate phase, May 284 drugs in, May 288-303 criteria for, May 288-303 rationale for, May 288-303 table of, May 293 fenofibrate in, May 303 gemfibrozil in, May 300 mevinolin in, May 302-303 813

Hyperlipoproteinemia (cont.) neomycin in, May 301-302 nicotinic acid in, May 296-297 phenotype definitions and associated disorders, May 260 probucol in, May 299-300 type II, May 263-274 type III, May 274-276 type IV, May 276-278 type V, May 278-279 Hypertriglyceridemia: exogenous, May 261-263 I

Ibuprofen: in rheumatoid arthritis, Jan. 25 Imaging: magnetic resonance, in multiple sclerosis, Sept. 564-565 Immune globulin: for prevention of hepatitis A virus, June 330 Immunizations: and multiple sclerosis, Sept. 578 Immunocompromised persons: treatment of herpes simplex virus infections in, Dec. 774-775 Immunodeficiency (see AIDS) Immunology: of multiple sclerosis, Sept. 544-545 Immunoprophylaxis (see Hepatitis, B virus, immunoprophylaxis) Immunosuppressed patients: intestinal disease in, Apr. 231-232 Indocin: in rheumatoid arthritis, Jan. 24 Indomethacin: in rheumatoid arthritis, Jan. 24 Infarction myocardial (see Myocardial infarction) ventricular, right, Aug. 487-492 right atrial pressure tracings in, Aug. 491 814

Inheritance: of panic disorder and agoraphobia, July 404-405 Injection, local in fibrositis, Nov. 702 in myofascial pain syndromes, Nov. 715-716 Inotropic agents: in left ventricular dysfunction after myocardial infarction, Aug. 481-485 Intention tremor: in multiple sclerosis, Sept. 583 Intestine (See also Gastrointestinal) disease in homosexual men, Apr. 225-231 in immunosuppressed patients, Apr. 231-232 spirochetosis, Apr. 198-199 Intra-aortic counterpulsation: in left ventricular dysfunction after myocardial infarction, Aug. 485-487 Irradiation: lymphoid, total, in rheumatoid arthritis, Jan. 52-53 Ischemia anterior circulation, Mar. 141-142 spinal cord, Mar. 143-145 Isospora: in diarrhea, Apr. 222 J Joint sites: in rheumatoid arthritis, Jan. 13 K Kidney reactions: to nonsteroidal anti-inflammatory drugs, Jan. 27-28 L Leukapheresis: in rheumatoid arthritis, Jan. 53

Leukemia lymphoblastic, acute curability, Oct. 604-608 lymphocyte ontogeny related to, Oct. 606 myeloblastic, acute, curability, Oct. 625-631 Leukocytes: fecal, in diarrhea, Apr. 235 Lhermitte's symptom, Sept. 557-558 Life events: in panic disorder and agoraphobia, July 415 Lifestyles: and multiple sclerosis, Sept. 578 Lip: in herpes simplex, Dec. 735 Lipid(s) lowering in hyperlipoproteinemia, May 280-284 predictions in hypercholesterolemia, May 284-285 of white matter, Sept. 537 Lipoproteins, May 253-258 composition, May 253-258 effect of dietary components on, May 280 low-density, Metabolism by nonhepatic tissues, May 270-271 metabolism, May 253-258 properties of, May 254 synthesis, May 253-258 Livedo reticularis, Nov. 685 Liver: reactions to nonsteroidal anti-inflammatory drugs, Jan. 27 LPL deficiency: familial, May 261 Lundberg: plateau waves of, Mar. 139-141 Lung manifestations of rheumatoid arthritis, Jan. 60-61 neoplasms, small-cell curability, Oct. 635-637 limited, long-term survival in, Oct. 636

Lymphoblastic leukemia (see Leukemia, lymphoblastic) Lymphocyte: ontogeny related to acute lymphoblastic leukemia, Oct. 606 Lymphoid irradiation: total, in rheumatoid arthritis, Jan. 52-53 Lymphoma Burkitt's, curability, Oct. 634 diffuse large-cell chemotherapy regimens, Oct. 633 curability, Oct. 632-634 non-Hodgkin's chemotherapy regimens, glossary of, Oct. 598-599 curability, Oct. 632-634

M Magnetic resonance imaging: in multiple sclerosis, Sept. 564-565 Malformations: Chiari, Mar. 150-151 Maternal (see Herpes simplex virus, infection, maternal) Meclofenamate: in rheumatoid arthritis, Jan. 25-26 Meclomen: in rheumatoid arthritis, Jan. 25-26 Medicolegal considerations: in fibrositis management, Nov. 702-703 Methotrexate: in rheumatoid arthritis, Jan. 49-52 Mevinolin: in hyperlipoproteinemia, May 302-303 Mitral valve prolapse and panic disorder and agoraphobia, July 410-412 regurgitation after myocardial infarction, Aug. 493-497 MMPI T-scores: in fibrositis, Nov. 696 815

Monitoring: hemodynamic, in acute myocardial infarction, Aug. 460-464 Monocular visual loss: in multiple sclerosis, Sept. 552-555 Motrin: in rheumatoid arthritis, Jan. 25 Movement-induced dystonia, Mar. 151-152 MRI: in multiple sclerosis, Sept. 564-565 MS (see Multiple sclerosis) Multiple sclerosis, Sept. 523-589 acute relapse, treatment, Sept. 584-585 amyotrophies in, Sept. 561 ataxia in, Sept. 583 background, Sept. 541-547 bladder disturbances in, Sept. 582-583 bowel dysfunction in, Sept. 583 chronic progressive, treatment, Sept. 585-586 clinical course, Sept. 568-575 complications, treatment, Sept. 581 CSF abnormalities in, Sept. 565-568 delivery and, Sept. 577-578 demyelination in, experimental, Sept. 545-547 diagnosis, Sept. 549-562, 575-576 laboratory studies in, Sept. 563-568 dissemination in space in, Sept. 563 epidemiology, Sept. 530-535 evoked potentials in, Sept. 563-564 facial myokymia in, Sept. 560-561 fatigue in, Sept. 583-584 genetics, Sept. 530-535, 541-542, 577 heat sensitivity in, Sept. 562 management, Sept. 579 immunizations and, Sept. 578 immunology, Sept. 544-545 816

intention tremor in, Sept. 583 Lhermitte's symptom and, Sept. 557-558 lifestyles and, Sept. 578 magnetic resonance imaging in, Sept. 564-565 management, Sept. 575-586 general, Sept. 575-584 specific, Sept. 584-586 supportive, Sept. 575-584 myelitis and, acute transverse, Sept. 558-559 ophthalmoplegia in, internuclear, Sept. 555-557 optic neuritis in, Sept. 552-555 pain in, Sept. 583 paroxysmal symptoms in, Sept. 560, 561 pathogenesis, Sept. 541-547 pathology, Sept. 535-549 pathophysiology, Sept. 547-548 patients initially diagnosed as, other final diagnoses in, Sept. 551 patterns of onset highly characteristic of, Sept. 552-562 pregnancy in, Sept. 577-578 prognosis, Sept. 568-575, 576-577 proprietary treatment, Sept. 578-579 quack treatment, Sept. 578-579 radicular syndromes in, Sept. 561 spasticity in, Sept. 581-582 stressful events and, Sept. 578 surgery and, Sept. 578 symptomatic therapy, Sept. 581 symptoms, initial, Sept. 552 tic douloureux and, Sept. 557 tomography in, computed, Sept. 564-565 transmissibility in, Sept. 579 useless hand syndrome and, Sept. 559-560 viruses in, Sept. 542-544 visual loss in, monocular, Sept. 552-555

Muscle abnormalities in fibrositis, Nov. 689-691 biopsy in myofascial pain syndromes, Nov. 712-713 cramps, Nov. 663 pain, Nov. 660-668 approach to patient with, Nov. 666 chronic, Nov. 665 clinical syndromes of, Nov. 663-668 with exercise, Nov. 663 after exertion, Nov. 665 local, in myofascial pain syndromes, Nov. 711 pathogenesis, Nov. 662-663 with weakness, Nov. 663 papillary, dysfunction, and myocardial infarction, Aug. 496 spindles, Nov. 662 structural abnormalities, Nov. 662 swollen, Nov. 663 tender, Nov. 663 Muscular rheumatism: Nov. 668 Musculoskeletal pain causes of, Nov. 661 diffuse, in fibrositis, Nov. 670, 675 Myobacterial infections: in diarrhea, Apr. 202-207 Myelitis: acute transverse, Sept. 558-559 Myeloblastic leukemia: acute, curability, Oct. 625-631 Myocardial infarction, May 290 Myocardial infarction, acute afterload in, Aug. 456-459 contractility in, Aug. 459 free wall rupture after, Aug. 502-503 heart rate in, Aug. 459-460 hemodynamic abnormalities in, Aug. 451-514 pathophysiology, Aug. 451-460

hemodynamic classification of patients with, Aug. 468-472 Forrester, Aug. 470 hemodynamic monitoring in, Aug. 460-464 mechanical defects complicating, Aug. 493-503 mitral regurgitation after, Aug. 493-497 preload and, Aug. 452-456 ventricular dysfunction after, left clinical significance of, Aug. 464-468 diuretics in, Aug. 473-474 fluid therapy in, Aug. 472-473 inotropic agents in, Aug. 481-485 intra-aortic counterpulsation in, Aug. 485-487 nitrates in, Aug. 476-478 sodium nitroprusside in, Aug. 478-481 therapy, Aug. 472-487 vasodilators in, Aug. 475-481 ventricular septal rupture after, Aug. 497-502 Myofascial pain syndromes, Nov. 670, 671-672, 704-717 associated features, Nov. 709 clinical findings, Nov. 704-705 definition, Nov. 670 diagnosis, differential, Nov. 709-710 discussion of term, Nov. 659 electromyography in, Nov. 711-712 injection in, local, Nov. 715-716 local muscle pain in, Nov. 711 muscle biopsy in, Nov. 712-713 pathogenesis, Nov. 710-713 referred pain in, Nov. 706, 708-709 removal of activating/ perpetuating factors in, Nov. 713-714 stretch-and-spray in, Nov. 714-715 treatment, Nov. 713-717 817

Myofascial pain syndromes (cont.) trigger points in, Nov. 671, 704, 705-708 active, Nov. 707 latent, Nov. 707 Myokymia: facial, in multiple sclerosis, Sept. 560-561 N

Nalfon: in rheumatoid arthritis, Jan. 25 Naprosyn: in rheumatoid arthritis, Jan. 25 Naproxen: in rheumatoid arthritis, Jan. 25 Neck neoplasms: curability, Oct. 634-635 Neomycin: in hyperlipoproteinemia, May 301-302 Neonatal (see Newborn) Neoplasms anal, curability, Oct. 631-632 breast, curability, Oct. 637 curable, Oct. 604-625 gestational trophoblastic (see Gestational trophoblastic neoplasms) head, curability, Oct. 634-635 lung (see Lung, neoplasms) neck, curability, Oct. 634-635 ovarian, curability, Oct. 638 potentially curable, Oct. 602-652 future directions, Oct. 634-638 testicular (see Testicular neoplasms) Nerve(s) endings, nocioceptive, Nov. 662 peripheral, in posture, Mar. 134-135 Nervous system: central, reactions to nonsteroidal antiinflammatory drugs, Jan. 28 Neuralgia: trigeminal, Sept. 557 Neuritis (see Optic neuritis) 818

Neurocirculatory asthenia, July 397 Neuropathy: peripheral, Mar. 147-148 Neurosis (see Panic disorder and agoraphobia) Neurotransmitters: in panic disorder and agoraphobia, July 412-413 Newborn of HBsAg-positive mothers, June 355 herpes (see Herpes simplex virus, infection, neonatal) Nicotinic acid: in hyperlipoproteinemia, May 296-297 Nitrates: in left ventricular dysfunction after myocardial infarction, Aug. 476-478 Nitroprusside: in left ventricular dysfunction after myocardial infarction, Aug. 478-481 Nociceptive nerve endings, Nov. 662 Norwalk virus: in diarrhea, Apr. 209-210 Nostril: in herpes simplex, Dec. 735 NSAIDs (see Anti-inflammatory drugs, nonsteroidal) O Ophthalmoplegia: internuclear, in multiple sclerosis, Sept. 555-557 Oppenheim's useless hand syndrome, Sept. 559-560 Optic neuritis flow chart for use in diagnostic tests in, Sept. 567 in multiple sclerosis, Sept. 552-555 Oral (see Herpes simplex virus, infection, oral) Ovarian neoplasms: curability, Oct. 638

P Pain in multiple sclerosis, Sept. 583 muscle (see Muscle, pain) musculoskeletal (see Musculoskeletal pain) myofascial (see Myofascial pain syndromes) referred, Nov. 660 in myofascial pain syndromes, Nov. 706, 708-709 Palate: in herpes labialis, Dec. 741 Panic disorder and agoraphobia, July 394-444 behavior therapy in, July 432 benzodiazepine receptor and, July 413-414 biologic factors, July 405-414 clinical picture, July 416-419 cognitive therapy in, July 434-435 complications, July 420-421 course, July 420-421 diagnosis, July 394-397 differential, July 422-426 drugs in, July 427-432 early experiences in, July 415 epidemiology, July 399-401 experimentally induced panic attacks, July 407-410 family studies, July 402-403 genetics, July 401-405 history, July 397-399 inheritance mode, July 404-405 life events in, July 415 medical management, July 426427 mitral valve prolapse and, July 410-412 neurotransmitters in, July 412413 onset, July 419-420 age of, July 401 outcome, July 421-422 personality in, July 414-415 physical illness differentiated from, July 422-425

prevalence, July 399-401 psychiatric illness differentiated from, July 425-426 psychological factors, July 414-416 psychosurgery in, July 435 psychotherapy in, July 433 self-regulation therapies in, July 433-434 sex ratio in, July 401 social factors in, July 416 social skills training in, July 435 terms formerly used for, July 398 treatment, July 426-435 twin studies, July 403-404 Papillary muscle dysfunction: and myocardial infarction, Aug. 496 Pararotavirus: in diarrhea, Apr. 209 Parasitic infections: in diarrhea, Apr. 215-222 Parkinson's disease: and falls, Mar. 152-153 Paroxysmal symptoms: in multiple sclerosis, Sept. 560, 561 Penicillamine: and rheumatoid arthritis, Jan. 40-43 Penis: in herpes simplex, Dec. 755 Periarticular rheumatism, Nov. 660 Pericardial tamponade: right atrial pressure tracings in, Aug. 491 Perioral herpes labialis, Dec. 741 Personality: in panic disorder and agoraphobia, July 414-415 Pharyngotonsillitis: herpetic, Dec. 735 Phenylbutazone: in rheumatoid arthritis, Jan. 26 Physical fitness in fibrositis, Nov. 701 illness differentiated from panic disorder and agoraphobia, July 422-425 819

Physical (cont.) therapy in fibrositis, Nov. 702 Piroxicam: in rheumatoid arthritis, Jan. 26 Plasmapheresis: in rheumatoid arthritis, Jan. 53 Plateau waves: of Lundberg, Mar. 139-141 Plesiomonas shigelloides: in diarrhea, Apr. 199-201 Pneumonia: herpes labialis after, Dec. 741 Poisoning (see Food, poisoning) Polymyalgia rheumatica, Nov. 663, 667 Posture cerebellum in, Mar. 133 instability, in aged, Mar. 152 peripheral nerves in, Mar. 134-135 physiology of, Mar. 127-135 propriospinal tracts in, Mar. 132-133 reticulospinal tracts in, Mar. 131 spinal cord in, Mar. 134-135 vestibulospinal tracts in, Mar. 129-131 Pregnancy anti-inflammatory drugs and, nonsteroidal, Jan. 28 in multiple sclerosis, Sept. 577-578 Preload: and acute myocardial infarction, Aug. 452-456 Prenatal screening: for hepatitis B surface antigen, June 356 Probucol: in hyperlipoproteinemia, May 299-300 Propriospinal tracts: in posture, Mar. 132-133 Proteins: of white matter, Sept. 537 Psychiatric illness: differentiated from panic disorder and agoraphobia, July 425-426 Psychological factors in panic disorder and agoraphobia, July 414-416 820

studies in fibrositis, Nov. 693-698 Psychosocial counseling: in genital herpes, Dec. 785-797 Psychosurgery: in panic disorder and agoraphobia, July 435 Psychotherapy: in panic disorder and agoraphobia, July 433 Pulmonary (See also Lung) capillary wedge pressure related to diastolic pressure in left ventricle, Aug. 455

R

Radiation: lymphoid, total, in rheumatoid arthritis, Jan. 52-53 Radicular syndromes: in multiple sclerosis, Sept. 561 Rectum: infections, Chlamydia trachomatis in, Apr. 205 Referred pain, Nov. 660 in myofascial pain syndromes, Nov. 706, 708-709 Renal reactions: to nonsteroidal anti-inflammatory drugs, Jan. 27-28 Resins: bile acid sequestering, in hyperlipoproteinemia, May 294-296 Reticulospinal tracts: in posture, Mar. 131 Rheumatic disorder: prevalence of tender points in, Nov. 683 Rheumatism muscular, Nov. 668 nonarticular, Nov. 660-668 periarticular, Nov. 660 Rheumatoid arthritis, Jan. 9-74 anti-inflammatory drugs in, nonsteroidal, Jan. 23-28 adverse reactions to, Jan. 27-28 antimalarials in, Jan. 44-45 apheresis in, Jan. 53

azathioprine in, Jan. 46-48 azolid in, Jan. 26 butazolidin in, Jan. 26 cervical spine disease in, Jan. 62 chloroquine in, Jan. 44-45 clinoril in, Jan. 24 combination therapy of, Jan. 52 cyclophosphamide in, Jan. 48-49 cytotoxic therapy in, Jan. 46 diflunisal in, Jan. 26 dolobid in, Jan. 26 epidemiology, Jan. 9-10 etiology, Jan. 10-12 experimental medications, Jan. 53 extra-articular manifestations, Jan. 56-63 feldene in, Jan. 26 fenoprofen in, Jan. 25 gold and, Jan. 34-40 hydroxychloroquine in, Jan. 44-45 ibuprofen in, Jan. 25 indocin in, Jan. 24 indomethacin in, Jan. 24 joint sites, frequency of involvement, Jan. 13 leukapheresis in, Jan. 53 lymphoid irradiation in, total, Jan. 52-53 management algorithms, Jan. 54-56 manifestations, clinical, Jan. 12-15 meclofenamate in, Jan. 25-26 meclomen in, Jan. 25-26 medical therapy, Jan. 19-53 methotrexate in, Jan. 49-52 motrin in, Jan. 25 nalfon in, Jan. 25 naprosyn in, Jan. 25 naproxen in, Jan. 25 pathogenesis, Jan. 10-12 penicillamine and, Jan. 40-43 phenylbutazone in, Jan. 26 piroxicam in, Jan. 26 plasmapheresis in, Jan. 53

pulmonary manifestations, Jan. 60-61 rufen in, Jan. 25 salicylates in, Jan. 20-23 sulindac in, Jan. 24 surgery of, Jan. 63-66 tolectin in, Jan. 24-25 tolmetin in, Jan. 24-25 treatment, Jan. 15-53 general approach to patient, Jan. 15-18 Rheumatoid vasculitis, Jan. 56-57 Rotavirus: in diarrhea, Apr. 207 -209 Rufen: in rheumatoid arthritis, Jan. 25 Rupture free wall, after myocardial infarction, Aug. 502-503 ventricular septal, in myocardial infarction, Aug. 497-502 S

Salicylates: in rheumatoid arthritis, Jan. 20-23 Salmonella: in diarrhea, Apr. 184-185 Sarcomas: curability, Oct. 637-638 Sclerosis (see Multiple sclerosis) SCL-90-R T scores: for fibrositis, Nov. 697 Seizures: epileptic, Mar. 155-156 Self-regulation therapies: in panic disorder and agoraphobia, July, 433-434 Septal rupture: ventricular, in myocardial infarction, Aug. 497-502 Serum glutamic oxaloacetic transaminase: in non-A, non-B hepatitis, J u n e 372 Sex ratio: in panic disorder and agoraphobia, July 401 Sexual contact, and hepatitis B virus, J u n e 354 partner, and genital herpes, 821

Sexual (cont.) suggestions for '~telling," Dec. 792 SGOT: in non-A, non-B hepatitis, June 372 Shigella: in diarrhea, Apr. 185-186 Shock (see Toxic shock syndrome) ~-Sitosterol: in hyperlipoproteinemia, May 302 Sj6gren's syndrome, Jan. 58-60 Skin (see Cutaneous) Sleep disturbance in fibrositis, Nov. 676-677, 692-693 management, Nov. 701-702 Social factors in panic disorder and agoraphobia, July 416 skills training in panic disorder and agoraphobia, July 435 Sodium nitroprusside: in left ventricular dysfunction after myocardial infarction, Aug. 478-481 Spasticity: in multiple sclerosis, Sept. 581-582 Spine cervical spine disease in rheumatoid arthritis, Jan. 62 cord compression, Mar. 145-147 damage, diagnostic evaluation, flow chart for, Sept. 568 ischemia, Mar. 143-145 in posture, Mar. 134-135 Spirochetosis: intestinal, Apr. 198-199 Staphylococcus aureus: toxic shock syndrome strains of, characteristics, Feb. 109 Stiffness: in fibrositis, Nov. 670, 675 Still's disease: adult onset, Jan. 61-62 Stomach (See also Gastrointestinal) 822

antrum, Campylobacter-like organisms of, Apr. 197-198 Stressful events: and multiple sclerosis, Sept. 578 Stretch-and-spray: in myofascial pain syndromes, Nov. 714-715 Stroke volume: effect of afterload on, Aug. 457 Sulindac: in rheumatoid arthritis, Jan. 24 Sun bathing: herpes labialis after, Dec. 744 Surgery: and multiple sclerosis, Sept. 578 Syncope: cough, and falls, Mar. 159-160 T Tamponade: pericardial, right atrial pressure tracings in, Aug. 491 Taut band, Nov. 704 Tender points (see Fibrositis, tender points in) Tendon organs: Golgi, Nov. 662 Testicular cancer, staging of, Oct. 617 neoplasms curability, Oct. 615-622 germ cell, proposed scheme for development of, Oct. 616 Tic doloureux, Sept. 557 Tolectin: in rheumatoid arthritis, Jan. 24-25 Tolmetin: in rheumatoid arthritis, Jan. 24-25 Tomography: computed, in multiple sclerosis, Sept. 564-565 Toxic shock syndrome, Feb. 82-118 background, Feb. 82-84 case definition, Feb. 83 case reports, Feb. 92-98 cases between 1974-1983, Feb. 85

clinical aspects, Feb. 91-108 clinical course, Feb. 102-105 diagnosis, differential, Feb. 105-108 epidemiology, Feb. 84-86 manifestations, systemic, skin and mucous membrane, Feb. 96 microbial factors in, Feb. 108-111 pathogenesis, Feb. 108-111 physical examination in, Feb. 98-102 physical findings in, Feb. 98-102 postsurgical, conditions associated with, Feb. 90 prevention, Feb. 114-115 recurrent, definition for, Feb. 104 risk factors, Feb. 86-91 strains of Staphylococcus aureus, characteristics of, Feb. 109 symptoms, Feb. 95-98 therapy, Feb. 111-114 Transmissibility: in multiple sclerosis, Sept. 579 Travelers' diarrhea: infectious, Apr. 222-224 Tremor: intention, in multiple sclerosis, Sept. 583 Trigeminal neuralgia, Sept. 557 Trigger points (see Myofascial pain syndromes, trigger points in) Trophoblastic neoplasms (see Gestational trophoblastic neoplasms) Tumors (see Neoplasms) Twin studies: in panic disorder and agoraphobia, July 403-404 U Useless hand syndrome: in multiple sclerosis, Sept. 559-560

V

Vaccine, hepatitis B, June, 356-363 potential candidates for, June 363 preferred and cost-effective strategies for, June 361 Valve (see Mitral valve) Vasculitis: rheumatoid, Jan. 56-57 Vasodilators: in left ventricular function after acute myocardial infarction, Aug. 475-481 Ventricle function curve, Frank-Starling, Aug. 453 effects of vasodilators on, Aug. 475 left diastolic pressures in, related to pulmonary capillary wedge pressure, Aug. 455 dysfunction (see Myocardial infarction, acute, ventricular dysfunction after, left) free wall rupture after myocardial infarction, Aug. 502-503 volume-pressure relationship, Aug. 454 right, infarction, Aug. 487-492 right atrial pressure tracings in, Aug. 491 septal rupture in myocardial infarction, Aug. 497-502 Vertebrobasilar insufficiency, Mar. 154-155 Vestibule: disorders, Mar. 148-149 Vestibulospinal tracts: in posture, Mar. 129-131 Vibrio (see Diarrhea, Vibrio in) Virology of hepatitis A virus, June 321-322 B virus, June 331-334 D virus, June 364-365 Virus(es) adenoviruses types 40 and 41 in 823

Virus(es) (cont.) diarrhea, Apr. 211-212 cytomegalovirus in diarrhea, Apr. 212-213 in diarrhea, infectious, Apr. 207-215 hepatitis (see under Hepatitis) herpes (see Herpes) in multiple sclerosis, Sept. 542-544 Norwalk, in diarrhea, Apr. 209-210 pararotavirus in diarrhea, Apr. 209 rotavirus in diarrhea, Apr. 207-209 Visual loss: monocular, in multiple sclerosis, Sept. 552-555

824

W

White matter: proteins, lipids and glycolipids of, Sept. 537 X Xanthoma eruptive in type V hyperlipidemia, May 266 tendinous, in familial hypercholesterolemia, May 265 tuberous, in type III hyperlipidemia, May 267 Y Yersinia (see Diarrhea, Yersinia

in)